The year 2015 was remarkable for ProQR. We have started enrolling two clinical studies in cystic fibrosis patients and brought a second molecule forward for Leber’s congenital amaurosis. We grew our company to 125 talented and dedicated employees, expanded our headquarters in Leiden, NL and opened an office in Palo Alto, CA.

Download the Magazine and Annual Report 2015 to
read more about ProQR, our mission and progress.


ProQR was born from the dream to beat cystic fibrosis in just one child. Now ProQR has one goal. Use groundbreaking science to develop medicines that will transform the lives of patients with severe genetic disorders and their loved ones.

Play the movie to learn more about
what drives us at ProQR.

Changing lives

Changing lives is what drives us at ProQR Therapeutics. With a highly energetic team of professionals we strive to make a meaningful impact on the lives of patients and the people around them. By combining innovative technologies and entrepreneurism, ProQR is developing products to potentially transform the lives of patients suffering from severe genetic disorders.

Join Us

Read more about careers at ProQR

Applying top-notch science to develop drugs for patients in need is what drives us. With an ingenious and persistent team of pioneers we love to welcome people who can accelerate our mission. Do you think you are ready to become a ProQRian? Let us know! Read more

Severe Genetic Disorders

Read more about our programs for severe genetic disorders

More than 70,000 patients worldwide suffer from cystic fibrosis, a genetic disease with a limited life expectancy. Leber’s congenital amaurosis affects approximately 15,000 patients in the Western world and there is currently no disease modifying treatment available for this blinding disease. Learn more about our missions and how we aim to change the course of severe genetic disorders. Read more

Meet us